{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:18:22Z","timestamp":1793513902304,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer (BRCA) is a common malignancy in women, and its resistance to immunotherapy is a major challenge. Abnormal expression of genes is important in the occurrence and development of BRCA and may also affect the prognosis of patients. Although many BRCA prognosis model scores have been developed, they are only applicable to a limited number of disease subtypes. Our goal is to develop a new prognostic score that is more accurate and applicable to a wider range of BRCA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      BRCA patient data from The Cancer Genome Atlas database was used to identify breast cancer-related genes (BRGs). Differential expression analysis of BRGs was performed using the \u2018limma\u2019 package in R. Prognostic BRGs were identified using co-expression and univariate Cox analysis. A predictive model of four BRGs was established using Cox regression and the LASSO algorithm. Model performance was evaluated using K-M survival and receiver operating characteristic curve analysis. The predictive ability of the signature in immune microenvironment and immunotherapy was investigated.\n                      <jats:italic>In vitro<\/jats:italic>\n                      experiments validated POLQ function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our study identified a four-BRG prognostic signature that outperformed conventional clinicopathological characteristics in predicting survival outcomes in BRCA patients. The signature effectively stratified BRCA patients into high- and low-risk groups and showed potential in predicting the response to immunotherapy. Notably, significant differences were observed in immune cell abundance between the two groups.\n                      <jats:italic>In vitro<\/jats:italic>\n                      experiments demonstrated that POLQ knockdown significantly reduced the viability, proliferation, and invasion capacity of MDA-MB-231 or HCC1806 cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our 4-BRG signature has the potential as an independent biomarker for predicting prognosis and treatment response in BRCA patients, complementing existing clinicopathological characteristics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1331841","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T23:43:01Z","timestamp":1706830981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["A new 4-gene-based prognostic model accurately predicts breast cancer prognosis and immunotherapy response by integrating WGCNA and bioinformatics analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Wenlong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengbin","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.07.046","article-title":"A 23 gene-based molecular prognostic score precisely predicts overall survival of breast cancer patients","volume":"46","author":"Shimizu","year":"2019","journal-title":"EBioMedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa060096","article-title":"A five-gene signature and clinical outcome in non-small-cell lung cancer","volume":"356","author":"Chen","year":"2007","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14779","article-title":"Four transcription profile-based models identify novel prognostic signatures in oesophageal cancer","volume":"24","author":"Liu","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0227-4","article-title":"Dietary patterns and cancer risk","volume":"20","author":"Steck","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current landscape of immunotherapy in breast cancer: A review","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.12.008","article-title":"Checkpoint inhibitors in breast cancer - current status","volume":"63","author":"Polk","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111687","article-title":"Immunotherapy in breast cancer: when, how, and what challenges","volume":"9","author":"Henriques","year":"2021","journal-title":"Biomedicines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.09.001","article-title":"Breast cancer: multiple subtypes within a tumor","volume":"3","author":"Yeo","year":"2017","journal-title":"Trends Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.humpath.2010.08.026","article-title":"The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal\/multicentric invasive ductal carcinoma of breast","volume":"43","author":"Choi","year":"2012","journal-title":"Hum Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9s","DOI":"10.2967\/jnumed.115.157834","article-title":"Clinical diagnosis and management of breast cancer","author":"McDonald","year":"2016","journal-title":"J Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1149193","article-title":"Predicting the immune microenvironment and prognosis with a anoikis - related signature in breast cancer","volume":"13","author":"Lu","year":"2023","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.795600","article-title":"A novel platelet-related gene signature for predicting the prognosis of triple-negative breast cancer","volume":"9","author":"Xie","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B20","article-title":"A prognostic model related to necrotizing apoptosis of breast cancer based on biorthogonal constrained depth semi-supervised nonnegative matrix decomposition and single-cell sequencing analysis","volume":"13","author":"Gao","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107886","article-title":"Breast cancer immunotherapy: current and novel approaches","volume":"98","author":"Barzaman","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12885-018-4441-3","article-title":"Mechanisms of immune evasion in breast cancer","volume":"18","author":"Bates","year":"2018","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7554","article-title":"Role of immunotherapy in triple-negative breast cancer","volume":"18","author":"Keenan","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188593","article-title":"Progress and challenges of immunotherapy in triple-negative breast cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01177-z","article-title":"Breast cancer immunotherapy: A comprehensive review","volume":"23","author":"Keshavarz","year":"2023","journal-title":"Clin Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.12.003","article-title":"Pd-L1 status in breast cancer: current view and perspectives","volume":"72","author":"Vranic","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (Icis); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-019-1735-4","article-title":"Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy","volume":"64","author":"Fan","year":"2021","journal-title":"Sci China Life Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101598","article-title":"Crucial role of the C-terminal domain of hfq protein in genomic instability","volume":"8","author":"Parekh","year":"2020","journal-title":"Microorganisms"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114109","article-title":"Recent advances in ddr (DNA damage response) inhibitors for cancer therapy","volume":"230","author":"Cheng","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103621","article-title":"The role of parp inhibitors in gastrointestinal cancers","volume":"171","author":"Hanna","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143438","article-title":"Exploiting DNA damage repair in precision cancer therapy: brca1 as a prime therapeutic target","volume":"13","author":"Raimundo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000340","article-title":"Atr inhibitor azd6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-022-02469-0","article-title":"The role of DNA damage repair (Ddr) system in response to immune checkpoint inhibitor (Ici) therapy","volume":"41","author":"Shi","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-22-1124","article-title":"Targeting DNA repair with combined inhibition of nhej and mmej induces synthetic lethality in tp53-mutant cancers","volume":"82","author":"Patterson-Fortin","year":"2022","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.dnarep.2016.05.003","article-title":"DNA polymerase \u0398 (Polq), double-strand break repair, and cancer","volume":"44","author":"Wood","year":"2016","journal-title":"DNA Repair (Amst)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41467-023-37096-6","article-title":"Polymerase \u0398 Inhibition activates the cgas-sting pathway and cooperates with immune checkpoint blockade in models of brca-deficient cancer","volume":"14","author":"Patterson-Fortin","year":"2023","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13224","article-title":"Resistance to DNA repair inhibitors in cancer","volume":"16","author":"Baxter","year":"2022","journal-title":"Mol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1331841\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T23:43:04Z","timestamp":1706830984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1331841\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2024.1331841"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1331841","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"article-number":"1331841"}}